From the recent drop and numbers that we have so far, one with little knowledge can easily deduce that if glaxo has best of class results it is primelairly due to the use of their proprietary adjuvant. We don't know what adjuvant was used in MDG phase 1 study, we don't even know if they used some...?!!!!
https://research.dundeesecurities.com/Research/MDG102809.pdf
+ As someone said clearly before, this phase 1 study result are not significant in terms of immune response data, too less participant to have a real idea of the effectivness of the vaccine.
What we do know:
Brand new technology:
1- Easily to manufacture
2- Low cost
3- Low delay
4- Partnership possibilities in coming months
5- Reschearch contract with U.S. army
Hope we will have news on the MOU sooner than later. In this regard does someone knows when MDG is planning to give us detail of what is going on with Ajanta Pharma.. or with any other company/country.
As far as the latest 2 or 3 days; much more buyer than seller. accumulation.